Compare Gilead Sciences, Inc. (GILD) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Weibo Corp — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while Weibo Corp trades at $7.85 (market cap $1.91B). The key difference: Gilead Sciences, Inc. is far larger — about 85.6× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.88%). Which is the better fit depends on your goals.
| GILD | WB | |
|---|---|---|
Market Cap | $163.51B | $1.91B |
Sector | Health | Media |
52-Week High | $155.80 | $12.83 |
52-Week Low | $108.22 | $7.20 |
Enterprise Value | $178.05B | $1.18B |
Dividend Yield | 2.49% | 7.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Weibo (WB) trades at $7.875, up 2.81% today, with a bullish technical signal and strong valuation metrics like a P/E of 5.41 and P/B of 0.49. The company reported $449.02M net income for 2025, with a 25.55% margin, and maintains a robust cash position of $2.35B. Recent news highlights its inclusion in value stock lists and AI developments, while earnings have missed expectations in recent quarters.
The outlook is mixed: low valuations and an 8% dividend yield offer upside, but competitive pressures and earnings misses pose risks. Analyst consensus leans buy (45.45%), but sentiment is cautious due to user engagement challenges. Investors should weigh the deep value against structural headwinds in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
